Latanoprost - A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension

被引:53
作者
Patel, SS [1 ]
Spencer, CM [1 ]
机构
[1] ADIS INT LTD, AUCKLAND 10, NEW ZEALAND
关键词
D O I
10.2165/00002512-199609050-00007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Latanoprost is an ester prodrug analogue of prostaglandin F-2 alpha which effectively reduces intraocular pressure (IOP) by increasing uveoscleral outflow rather than altering conventional (trabeculo-canalicular) aqueous outflow. The IOP-lowering effect of latanoprost lasts for 20 to 24 hours after a single dose, which allows a single daily dosage regimen. Data from 4 randomised double-masked multicentre studies indicate that a once daily dose of topical latanoprost 0.005% is as effective as timolol 0.5% twice daily in the treatment of patients with primary open-angle glaucoma or ocular hypertension. A number of studies also demonstrate that latanoprost enhances IOP-lowering effects when applied in combination with other antiglaucoma agents. Latanoprost is well tolerated with no, or barely detectable, conjunctival hyperaemia, and, unlike timolol, is not associated with systemic adverse effects. However, 3 to 10% of patients treated with latanoprost 0.005% have shown increased iris pigmentation after 3 to 4.5 months treatment. In summary, the available data show that latanoprost is a potent IOP-lowering agent with a number of positive features including a single daily dosage regimen, a novel mechanism of action that enhances the IOP-lowering effect of contemporary agents, and a lack of systemic adverse effects. These properties suitably poise latanoprost for a prominent position in the management of patients with primary open-angle glaucoma and ocular hypertension.
引用
收藏
页码:363 / 378
页数:16
相关论文
共 82 条
[1]   PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS [J].
ALM, A ;
VILLUMSEN, J .
ARCHIVES OF OPHTHALMOLOGY, 1991, 109 (11) :1564-1568
[2]  
ALM A, 1993, OPHTHALMOLOGY, V100, P1312
[3]  
Alm A, 1989, Prog Clin Biol Res, V312, P447
[4]   LATANOPROST ADMINISTERED ONCE-DAILY CAUSED A MAINTAINED REDUCTION OF INTRAOCULAR-PRESSURE IN GLAUCOMA PATIENTS TREATED CONCOMITANTLY WITH TIMOLOL [J].
ALM, A ;
WIDENGARD, I ;
KJELLGREN, D ;
SODERSTROM, M ;
FRISTROM, B ;
HEIJL, A ;
STJERSCHANTZ, J .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (01) :12-16
[5]   Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol [J].
Alm, A ;
Stjernschantz, J ;
Widengard, I ;
Linden, C ;
Soderstrom, M ;
Nilsson, SE ;
Fristrom, B ;
Lindblom, B ;
Heijl, A ;
Gundersen, KG ;
Ehinger, B ;
Holmin, C ;
BengtssonStigmar, E ;
Aasved, H ;
Jangard, P ;
Ringvold, A ;
Vegge, T ;
Halseide, R ;
LundAndersen, H ;
Flesner, P ;
Thygesen, J ;
Airaksinen, J ;
Tuulonen, A .
OPHTHALMOLOGY, 1995, 102 (12) :1743-1752
[6]  
ALM A, 1993, CURR OPIN OPHTHALMOL, V4, P44
[7]  
ALM A, 1992, P ASS RES VIS OPHTH
[8]  
ALM A, 1994, P 27 INT C OPHTH JUN
[9]   ABSORPTION OF OCULAR TIMOLOL [J].
ALVAN, G ;
CALISSENDORFF, B ;
SEIDEMAN, P ;
WIDMARK, K ;
WIDMARK, G .
CLINICAL PHARMACOKINETICS, 1980, 5 (01) :95-100
[10]   CORNEAL PERMEABILITY TO AND OCULAR METABOLISM OF PHENYL-SUBSTITUTED PROSTAGLANDIN ESTERS IN-VITRO [J].
BASU, S ;
SJOQUIST, B ;
STJERNSCHANTZ, J ;
RESUL, B .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1994, 50 (04) :161-168